NASDAQ:SCLN - 218200 Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$11.15
+0.30 (1.20%)
Get New 218200 Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCLN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for 218200 in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $11.15.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in 218200. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Maxim GroupReiterated RatingBuy ➝ HoldLow
i
Rating by Gabrielle Zhou at Maxim Group
5/11/2017Maxim GroupSet Price TargetBuy$17.00 ➝ $14.00High
i
Rating by Gabrielle Zhou at Maxim Group
3/6/2017Maxim GroupSet Price TargetBuy$14.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
1/17/2017Maxim GroupSet Price TargetBuy$14.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
11/28/2016Maxim GroupInitiated CoverageBuy$14.00N/A
i
(Data available from 2/28/2016 forward)
218200 logo
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.
Read More

Today's Range

Now: $11.15
$11.15
$11.15

50 Day Range

MA: N/A

52 Week Range

Now: $11.15
$8.55
$11.43

Volume

N/A

Average Volume

444,833 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 218200?

The following sell-side analysts have issued reports on 218200 in the last twelve months:
View the latest analyst ratings for SCLN.

What is the current price target for 218200?

0 Wall Street analysts have set twelve-month price targets for 218200 in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for 218200 in the next year.
View the latest price targets for SCLN.

What is the current consensus analyst rating for 218200?

218200 currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SCLN.

What other companies compete with 218200?

How do I contact 218200's investor relations team?

218200's physical mailing address is 950 Tower Ln Ste 900, FOSTER CITY, CA 94404-2125, United States. The specialty pharmaceutical company's listed phone number is +1-650-3583456. The official website for 218200 is www.sciclone.com.